参考文献/References:
[1] Wilson PWF,Polonsky TS,Miedema MD,et al. Systematic review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. J Am Coll Cardiol,2019,73:3210-3227.
[2] Khera AV,Kathiresan S. Genetics of coronary artery disease:discovery,biology and clinical translation[J]. Nat Rev Genet,2017,18(6):331-344.
[3] Zheng X,Curtis JP,Hu S, et al. Coronary catheterization and percutaneous coronary intervention in China:10-year results from the China PEACE-Retrospective Cathpci Study[J]. JAMA Intern Med,2016,176(4):512-521.
[4] Hu G,Tuomilehto J,Borodulin K,et al. The joint associations of occupational,commuting,and leisure-time physical activity,and the Framingham risk score on the 10-year risk of coronary heart disease[J]. Eur Heart J,2007,28(4):492-498.
[5] Edlinger M,Wanitschek M,D?rler J,et al. External validation and extension of a diagnostic model for obstructive coronary artery disease:a cross-sectional predictive evaluation in 4888 patients of the Austrian Coronary Artery disease Risk Determination In Innsbruck by diaGnostic ANgiography (CARDⅡGAN) cohort[J]. BMJ Open,2017,7(4):e014467.
[6] Lee YH,Bang H,Kim DJ. How to establish clinical prediction models[J]. Endocrinol Metab (Seoul),2016,31(1):38-44.
[7] Han K,Song K,Choi BW. How to develop,validate,and compare clinical prediction models involving radiological parameters:study design and statistical methods[J]. Korean J Radiol,2016,17(3):339-350.
[8] Lee TH,Cook EF,Goldman L. Prospective evaluation of a clinical and exercise-test model for the prediction of left main coronary artery disease[J]. Med Decis Making,1986,6(3):136-144.
[9] Wilson PW,D’agostino RB,Levy D,et al. Prediction of coronary heart disease using risk factor categories[J]. Circulation,1998,97(18):1837-1847.
[10] D’Agostino RB Sr,Vasan RS,Pencina MJ,et al. General cardiovascular risk profile for use in primary care:the Framingham Heart Study[J]. Circulation,2008,117(6):743-753.
[11] Koz C,Baysan O,Hasimi A,et al. Conventional and non-conventional coronary risk factors in male premature coronary artery disease patients already having a low Framingham risk score[J]. Acta Cardiol,2008,63(5):623-628.
[12] Sayin MR,Cetiner MA,Karabag T,et al. Framingham risk score and severity of coronary artery disease[J]. Herz,2014,39(5):638-643.
[13] Wynants L,Kent DM,Timmerman D,et al. Untapped potential of multicenter studies:a review of cardiovascular risk prediction models revealed inappropriate analyses and wide variation in reporting[J]. Diagn Progn Res,2019,3:6.
[14] Conroy RM,Pyorala K,Fitzgerald AP,et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe:the SCORE project[J]. Eur Heart J,2003,24(11):987-1003.
[15] Versteylen MO,Joosen IA,Shaw LJ,et al. Comparison of Framingham,PROCAM,SCORE,and Diamond Forrester to predict coronary atherosclerosis and cardiovascular events[J]. J Nucl Cardiol,2011,18(5):904-911.
[16] Guaricci AI,Pontone G,Fusini L,et al. Additional value of inflammatory biomarkers and carotid artery disease in prediction of significant coronary artery disease as assessed by coronary computed tomography angiography[J]. Eur Heart J Cardiovasc Imaging,2016,18(9):1049-1056.
[17] Graffigna MN,Berg G,Migliano M,et al. Ten years cardiovascular risk estimation according to Framingham score and non HDL-cholesterol in blood donors[J]. Diabetes Metab Syndr,2015,9(1):24-27.
[18] Chen S,Liu Y,Islam SMS,et al. A simple prediction model to estimate obstructive coronary artery disease[J]. BMC Cardiovasc Disord,2018,18(1):7.
[19] Liu Y,Li Q,Chen S,et al. A simple modified Framingham Scoring system to predict obstructive coronary artery disease[J]. J Cardiovasc Transl Res,2018,11(6):495-502.
[20] Hippisley-Cox J,Coupland C,Vinogradova Y,et al. Derivation and validation of QRISK,a new cardiovascular disease risk score for the United Kingdom:prospective open cohort study[J]. BMJ,2007,335(7611):136.
[21] Reeh J,Therming CB,Heitmann M,et al. Prediction of obstructive coronary artery disease and prognosis in patients with suspected stable angina[J]. Eur. Heart J,2019,40(18):1426-1435.
[22] Moons KG,Kengne AP,Woodward M,et al. Risk prediction models:Ⅰ. Development,internal validation,and assessing the incremental value of a new (bio)marker[J]. Heart,2012,98(9):683-690.
[23] Lan M,Liu B,He Q. Evaluation of the association between hyperuricemia and coronary artery disease:A STROBE-compliant article[J]. Medicine (Baltimore),2018,97(44):e12926.
[24] de Stefano A,Mannucci L,Tamburi F,et al. Lp-PLA,a new biomarker of vascular disorders in metabolic diseases[J]. Int J Immunopathol Pharmacol,2019,33:2058738419827154.
[25] 陈斌,王洪巨. 同型半胱氨酸、叶酸代谢与冠心病的研究进展[J]. 心血管病学进展,2018,39(2):291-294.
[26] Mosca L,Banka CL,Benjamin EJ,et al. Evidence-based guidelines for cardiovascular disease prevention in women:2007 update[J]. J Am Coll Cardiol,2007,49(11):1230-1250.
[27] Genders TS,Steyerberg EW,Hunink MG,et al. Prediction model to estimate presence of coronary artery disease:retrospective pooled analysis of existing cohorts[J]. BMJ,2012,344:e3485.
[28] Wessler BS,Lai Yh L,Kramer W,et al. Clinical prediction models for cardiovascular disease tufts predictive analytics and comparative effectiveness clinical prediction model database[J]. Circ Cardiovasc Qual Outcomes,2015,8(4):368-375.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(6):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(6):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(6):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(6):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(6):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(6):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(6):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(6):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]